Solis Minerals Ltd (TSX-V:SLMN, ASX:SLM, OTCQB:SLMFF, FRA:08WA) has kicked off diamond drilling at its 100%-owned Cinto Copper Project in southern Peru, beginning an initial program of around five holes for 2,500 metres designed to test high-priority porphyry copper targets.
The program will investigate coincident geochemical and geophysical anomalies, including targets generated by induced polarisation (IP) surveying and areas where previous surface sampling returned copper grades of up to 8.7%.
Lightning Minerals Ltd (ASX:L1M, FRA:YZ1) has defined two new gold target areas across the 5-kilometre-long Western Zone at its wholly owned Mt Turner Gold Project in northern Queensland, advancing the corridor from a conceptual target toward potential drill testing.
The results include a 1,000-metre-long gold anomaly in the northern part of the Western Zone associated with a broader 1,400-metre multi-element anomaly interpreted as a potential hydrothermal footprint. The gold anomaly remains open to the south, while the broader thermal vector anomaly remains open to the east.
88 Energy Ltd (AIM:88E, ASX:88E, OTCQB:EEENF, FRA:POQ) shares climbed on Tuesday after it told investors that its Namibia joint venture has applied to move PEL 93 into its next two-year exploration phase, putting at least one exploration well on the work programme as nearby drilling provides further evidence of hydrocarbons in the Owambo Basin.
The application covers a Second Renewal Exploration Period starting on 3 October 2026 and follows integration of around 6,000 line-kilometres of airborne geophysical data.
Breakthrough Minerals Ltd (ASX:BTM, FRA:24X) has delivered further high-grade copper-gold results from resource expansion drilling at the Turpentine deposit in North Queensland, strengthening the case for growth beyond the existing mineral resource.
Three new holes returned significant mineralisation, led by 5 metres at 3.21% copper equivalent (CuEq) from 137 metres in hole 26TUR005, comprising 2.96% copper and 0.31 g/t gold.
Optiscan Imaging Ltd (ASX:OIL) has initiated a US-based head and neck cancer imaging study with Mayo Clinic, expanding the clinical evaluation of its InVue™ and InForm™ platforms and generating data intended to support US FDA regulatory submissions later in 2026.
Patient recruitment is underway for the 35-patient study at Mayo Clinic Rochester, where the technologies will be assessed for their ability to evaluate surgical margins during head and neck tumour resections.
Greenvale Energy Ltd (ASX:GRV, OTC:GVLMF) has defined a large-scale potential uranium paleochannel target extending for around nine kilometres at the Powers Prospect within its Thunderball Uranium Project in the Northern Territory.
Field mapping and sampling have outlined a north-south trending target up to 400 metres wide, confirming an extensive airborne radiometric anomaly previously identified through Greenvale’s regional exploration work.
Frontier Energy Ltd (ASX:FHE, OTC:FRHYF) has executed all major equipment and construction contracts for Stage One of its Waroona Renewable Energy Project in Western Australia, materially reducing execution risk as the company prepares to begin site works this month.
Stage One comprises a 132-megawatt solar facility paired with an 81.5-megawatt, 6.9-hour battery energy storage system (BESS). Major equipment and construction contracts have been secured on a fixed-price basis and represent the majority of the project’s $310 million budget, with a further $22 million contingency. The development is fully funded.
Provaris Energy Ltd (ASX:PV1, OTC:GBBLF, FRA:WS90) has moved its compressed hydrogen technology closer to commercial-scale production after signing a technical collaboration agreement with China’s Himile Heavy Industries to develop a manufacturing pathway for its proprietary hydrogen tanks.
The agreement builds on Provaris’ prototype fabrication and class approval work in Norway and will assess large-scale production of tanks for the company’s H2Neo™ hydrogen carriers and H2Leo™ storage barges, as well as other potential applications.
Amazon.com Inc (NASDAQ:AMZN) shares closed 2.5% lower after the US Federal Trade Commission filed a lawsuit alleging the e-commerce giant manipulated advertising prices on its platform and extracted tens of billions of dollars from businesses over seven years.
The case, joined by a bipartisan group of more than 20 state attorneys general, alleges Amazon secretly increased the minimum price advertisers were required to pay to promote products on its marketplace.
CSL Limited (ASX:CSL) shares gained 1% to $173.36 in intraday trading as investors assessed new agreements with the Donald Trump-led US Administration that provide greater certainty around drug pricing and potential tariffs.
The biotech giant was among nine pharmaceutical companies named by the White House as signing up to Trump’s ‘most-favoured-nation’ (MFN) drug pricing framework.
For years, US banks viewed stablecoins as a potential threat to deposits and the traditional payments system. Now, a large section of the banking industry is preparing to put blockchain technology at the heart of its own financial infrastructure.
Thirty-nine US state bankers associations have formed the BankChain Alliance, an industry-owned initiative that plans to build a common blockchain network capable of supporting stablecoins, tokenised bank deposits, smart payments and automated settlement.
Nvidia Corp (NASDAQ:NVDA, XETRA:NVD) is making a US$3.5 billion strategic investment in Taiwan’s MediaTek as the artificial intelligence giant moves to protect its dominance from an emerging threat - its biggest customers increasingly designing AI chips of their own.
The investment, announced on August 31 through the purchase of MediaTek convertible bonds, comes alongside a substantial expansion of the companies’ partnership across data centres, personal computing and automotive technology.
Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) has secured approximately $4.77 million in additional funding after Forrest Capital Pty Ltd agreed to fully underwrite the exercise of the company’s remaining unlisted options.
The agreement comes as Actinogen approaches a potentially significant clinical milestone, with topline results from its pivotal XanaMIA Phase 2b/3 Alzheimer’s disease trial expected in November 2026.
Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has secured firm commitments for a $2.3 million institutional placement, providing full funding for its newly announced clinical trial of lead oncology candidate HMBD-002 in acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS).
HMBD-002 is being developed as a potential treatment for cancer, with Percheron now focused on moving the program into its next clinical phase while maintaining funding for its broader development activities.
Kingfisher Mining Ltd (ASX:KFM) has confirmed high-grade silver-lead-zinc mineralisation at the Stephens Trig prospect near Broken Hill, with its first drilling at the project since 2017 validating historical results and highlighting further exploration potential.
The maiden modern reverse circulation (RC) program comprised five holes for 584 metres and tested historically defined mineralisation at Stephens Trig, about 15 kilometres north of Broken Hill in New South Wales.